

SNMMI NEWSLINE

- 9N** 2021 SNMMI Image of the Year
- 10N** New Officers for SNMMI and SNMMI-TS
- 12N** JNM Editors' Choice Awards for 2020
- 12N** 2021 Henry N. Wagner, Jr., MD, SNMMI Annual Meeting Best Paper of the Year
- 13N** Outstanding JNMT Articles for 2020
- 14N** First Symposium of the European Working Group on the Radiobiology of Molecular Radiotherapy
Bart Cornelissen, Samantha Terry, Julie Nonnekens, and Jean-Pierre Pouget
- 16N** SNMMI Leadership Update: Nuclear Medicine Innovations: Providing Access for All
Richard Wahl
- 17N** Newsbriefs
- 19N** From the Literature

DISCUSSIONS WITH LEADERS

- 881** Perspectives on Radiopharmaceutical Agents from the FDA
Lou Marzella, Johannes Czernin, and Thomas Hope

HOT TOPICS

- 884** Pharmacogenomics in Radionuclide Therapy: Impact on Response to Theranostics
Andrew M. Scott and Lisa Bodei

CONTINUING EDUCATION

- 886** The Role of Nuclear Medicine in the Clinical Management of Benign Thyroid Disorders, Part 2: Nodular Goiter, Hypothyroidism, and Subacute Thyroiditis
Giuliano Mariani, Massimo Tonacchera, Mariano Grosso, Emilio Fiore, Pierpaolo Falchetta, Lucia Montanelli, Brunella Bagattini, Paolo Vitti, and H. William Strauss

FOCUS ON MOLECULAR IMAGING

- 896** Imaging Immunometabolism in Atherosclerosis
Philip Z. Mannes and Sina Tavakoli

SPECIAL CONTRIBUTION

- 903** ■ **INVITED PERSPECTIVE.** The Disappearing Act of Nuclear Medicine in The Netherlands: Just a New Trick by the Great Harry Houdini?
Johannes Czernin and Ken Herrmann
- 905** The New Integrated Nuclear Medicine and Radiology Residency Program in The Netherlands: Why Do Residents Choose to Subspecialize in Nuclear Medicine and Why Not?
Ton Velleman, Walter Noordzij, Rudi A.J.O. Dierckx, Yfke Ongena, and Thomas C. Kwee

COVID COMMENTARIES

- 910** Slow but Evident Recovery from Neocortical Dysfunction and Cognitive Impairment in a Series of Chronic COVID-19 Patients
Ganna Blazhenets, Nils Schroeter, Tobias Bormann, Johannes Thurow, Dirk Wagner, Lars Frings, Cornelius Weiller, Philipp T. Meyer, Andrea Dressing, and Jonas A. Hosp

EDITORIAL

- 916** Nuclear Medicine Beyond VISION
Wolfgang P. Fendler, Ken Herrmann, and Matthias Eiber

ONCOLOGY

Clinical

- 918** Early Treatment Response Assessment Using ¹⁸F-FET PET Compared with Contrast-Enhanced MRI in Glioma Patients After Adjuvant Temozolomide Chemotherapy
Garry Ceccon, Philipp Lohmann, Jan-Michael Werner, Caroline Tscherpel, Veronika Dunkl, Gabriele Stoffels, Jurij Rosen, Marion Rapp, Michael Sabel, Ulrich Herrlinger, et al.
- 926** ■ **FEATURED CLINICAL INVESTIGATION ARTICLE.** Response Evaluation and Survival Prediction After PD-1 Immunotherapy in Patients with Non-Small Cell Lung Cancer: Comparison of Assessment Methods
Narjess Ayati, Sze Ting Lee, S. Rasoul Zakavi, Melissa Cheng, W.F. Eddie Lau, Sagun Parakh, Kunthi Pathmaraj, and Andrew M. Scott

- 934** ¹¹C-Sorafenib and ¹⁵O-H₂O PET for Early Evaluation of Sorafenib Therapy
Lemonitsa H. Mammatas, Maqsood Yaqub, N. Harry Hendrikse, Otto S. Hoekstra, Richard J. Honeywell, Robert C. Schuit, Martijn Meijerink, Lothar A. Schwarte, Godefridus J. Peters, Henk M.W. Verheul, et al.

Basic

- 941** PARP1: A Potential Molecular Marker to Identify Cancer During Colposcopy Procedures
Paula Demétrio de Souza Franc, Navjot Guru, Abigail R. Kostolansky, Audrey Mauguen, Giacomo Pirovano, Susanne Kossatz, Sheryl Roberts, Marcio Abrahão, Snehal G. Patel, Kay J. Park, et al.

- 949** Ferronostics: Measuring Tumoral Ferrous Iron with PET to Predict Sensitivity to Iron-Targeted Cancer Therapies
Ning Zhao, Yangjie Huang, Yung-hua Wang, Ryan K. Muir, Ying-Chu Chen, Junnian Wei, Nima Hooshdaran, Pavithra Viswanath, Youngho Seo, Davide Ruggero, et al.

- 956** ■ **BRIEF COMMUNICATION.** Imaging Calreticulin for Early Detection of Immunogenic Cell Death During Anticancer Treatment
Dong-Yeon Kim, Ayoung Pyo, Misun Yun, Ramar Thangam, Sung-Hwan You, Ying Zhang, Ye-rim Jung, Dinh-Huy Nguyen, Akhil Venu, Hyeon Sik Kim, et al.

THERANOSTICS

Clinical

961 Biochemical Persistence of Prostate-Specific Antigen After Robot-Assisted Laparoscopic Radical Prostatectomy: Tumor Localizations Using PSMA PET/CT Imaging

Dennie Meijer, Maarten L. Donswijk, Yves J.L. Bodar, Pim J. van Leeuwen, Henk G. van der Poel, Wouter V. Vogel, Jakko A. Nieuwenhuijzen, N. Harry Hendrikse, Daniela E. Oprea-Lager, and André N. Vis

968 Positive Predictive Value and Correct Detection Rate of ¹⁸F-rhPSMA-7 PET in Biochemically Recurrent Prostate Cancer Validated by Composite Reference Standard

Maythinee Chantadisai, Gabriel Buschner, Markus Krönke, Isabel Rauscher, Thomas Langbein, Stephan G. Nekolla, Kilian Schiller, Matthias M. Heck, Tobias Maurer, Alexander Wurzer, et al.

975 ■ BRIEF COMMUNICATION. First Experiences with ¹⁷⁷Lu-PSMA Therapy in Combination with Pembrolizumab or After Pretreatment with Olaparib in Single Patients

Vikas Prasad, Friedemann Zengerling, Jochen P. Steinacker, Christian Bolenz, Meinrad Beer, Thomas Wiegel, Matthias Eiber, Neil Fleshner, and Ambros J. Beer

Basic

980 Preclinical Evaluation of ²¹³Bi- and ²²⁵Ac-Labeled Low-Molecular-Weight Compounds for Radiopharmaceutical Therapy of Prostate Cancer

Sangeeta Ray Banerjee, Ala Lisok, Il Minn, Anders Josefsson, Vivek Kumar, Mary Brummet, Srikanth Boinapally, Cory Brayton, Ronnie C. Mease, George Sgouros, et al.

989 ■ FEATURED ARTICLE OF THE MONTH. Mechanisms of Resistance to Prostate-Specific Membrane Antigen-Targeted Radioligand and Therapy in a Mouse Model of Prostate Cancer

Andreea D. Stuparu, Joseph R. Capri, Catherine A.L. Meyer, Thuc M. Le, Susan L. Evans-Axelsson, Kyle Current, Mark Lennox, Christine E. Mona, Wolfgang P. Fendler, Jeremie Calais, et al.

CARDIOVASCULAR

Clinical

996 ■ BRIEF COMMUNICATION. Cardiac β -Adrenergic Receptor Downregulation, Evaluated by Cardiac PET, in Chronotropic Incompetence

Toshihiko Goto, Shohei Kikuchi, Kento Mori, Takafumi Nakayama, Hidekatsu Fukuta, Yoshihiro Seo, Hitomi Narita, Akihiko Iida, and Nobuyuki Ohte

NEUROLOGY

Clinical

999 Toward a Universal Readout for ¹⁸F-Labeled Amyloid Tracers: The CAPTAINS Study

Gérard N. Bischof, Peter Bartenstein, Henryk Barthel, Bart van Berckel, Vincent Doré, Thilo van Eimeren, Norman Foster, Jochen Hammes, Adriaan A. Lammertsma, Satoshi Minoshima, et al.

RADIOBIOLOGY/DOSIMETRY

Clinical

1006 Feasibility of Single-Time-Point Dosimetry for Radiopharmaceutical Therapies

Xinchi Hou, Julia Brosch, Carlos Uribe, Alessandro Desy, Guido Böning, Jean-Mathieu Beaugard, Anna Celler, Arman Rahmim

RADIOCHEMISTRY

Basic

1012 ■ BRIEF COMMUNICATION. Cyclotron-Produced ¹³²La as a PET Imaging Surrogate for Therapeutic ²²⁵Ac

Eduardo Alucio-Sarduy, Todd E. Barnhart, Jamey Weichert, Reinier Hernandez, and Jonathan W. Engle

CHALLENGING CASE STUDIES

1016 Liver Enzyme Elevation After ¹⁷⁷Lu-PSMA Radioligand Therapy for Metastasized Castration-Resistant Prostate Cancer

Hannes Treiber, Alexander König, Albrecht Neesse, Annika Richter, Carsten Oliver Sahlmann, and Arne Strauss

LETTERS TO THE EDITOR

1020 Potential Use of Radiolabeled Antibodies for Imaging and Treatment of COVID-19

Ekaterina Dadachova

1020 Reply: Potential Use of Radiolabeled Antibodies for Imaging and Treatment of COVID-19

Nagavarakishore Pillarsetty, Lukas M. Carter, Jason S. Lewis, and Thomas Reiner

1021 The Importance of an Adequate Surgical Template During Salvage Lymph Node Dissection for Node-Recurrent Prostate Cancer

Carlo Andrea Bravi, Nicola Fossati, Giorgio Gandaglia, Nazareno Suardi, Francesco Montorsi, and Alberto Briganti

1022 Reply: The Importance of an Adequate Surgical Template During Salvage Lymph Node Dissection for Node-Recurrent Prostate Cancer

Wolfgang Peter Fendler and Andrea Farolfi

1022 V/Q SPECT/CT in the Time of COVID-19: Changing the Order to Improve Safety Without Sacrificing Accuracy

Wolfgang M. Schaefer, D. Knollmann, and Philipp T. Meyer

DEPARTMENTS

7A This Month in JNM

1015 Errata